Opiant Pharmaceuticals, Inc. Announces Establishment of Audit, Compensation and Nominating and Corporate Governance Committees
“When we established our milestones and objectives for 2017, key among them was the strengthening of our corporate governance,” said Dr.
The composition of the Committees is as follows:
Nominating and Corporate Governance Committee
All three committees are comprised solely of directors who meet the independence requirements under the NASDAQ Stock Market Listing Rules.
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.
CONTACT INFORMATION: Corporate Contact: Investor.firstname.lastname@example.org Media:
Susan FormanDGI email@example.com 212-825-3210 Investors: Glenn GarmontSenior Vice President Argot Partnersglenn@argotpartners.com 212-600-1902